David R. Guyer Sells 3,798 Shares of Ophthotech Corp (OPHT) Stock

Ophthotech Corp (NASDAQ:OPHT) insider David R. Guyer sold 3,798 shares of Ophthotech stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $3.17, for a total transaction of $12,039.66. Following the sale, the insider now owns 42,458 shares of the company’s stock, valued at $134,591.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ophthotech Corp (OPHT) traded up $0.06 during mid-day trading on Friday, hitting $2.85. 229,639 shares of the company’s stock traded hands, compared to its average volume of 464,522. The stock has a market capitalization of $102.71, a P/E ratio of 1.83 and a beta of 1.58. Ophthotech Corp has a 52-week low of $2.24 and a 52-week high of $5.05.

Several brokerages have issued reports on OPHT. TheStreet upgraded shares of Ophthotech from an “e+” rating to a “c” rating in a research report on Thursday, November 30th. ValuEngine lowered shares of Ophthotech from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Stifel Nicolaus reissued a “hold” rating and set a $4.00 price target on shares of Ophthotech in a research note on Thursday, September 21st. Finally, Zacks Investment Research raised shares of Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price target on the stock in a research note on Monday, November 13th.

Hedge funds have recently bought and sold shares of the business. Federated Investors Inc. PA increased its stake in shares of Ophthotech by 102.3% in the second quarter. Federated Investors Inc. PA now owns 55,461 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 28,040 shares during the period. Schwab Charles Investment Management Inc. increased its position in Ophthotech by 73.2% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 118,166 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 49,928 shares during the period. Geode Capital Management LLC increased its position in Ophthotech by 3.2% during the 1st quarter. Geode Capital Management LLC now owns 240,571 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 7,501 shares during the period. First Manhattan Co. purchased a new position in Ophthotech during the 3rd quarter valued at $1,201,000. Finally, Goldman Sachs Group Inc. increased its position in Ophthotech by 28.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 652,992 shares of the biopharmaceutical company’s stock valued at $1,672,000 after purchasing an additional 143,349 shares during the period. 62.48% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “David R. Guyer Sells 3,798 Shares of Ophthotech Corp (OPHT) Stock” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://ledgergazette.com/2018/01/12/ophthotech-corp-opht-insider-sells-12039-66-in-stock.html.

About Ophthotech

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Insider Buying and Selling by Quarter for Ophthotech (NASDAQ:OPHT)

Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply